Suppliers and packagers for ORENITRAM

ORENITRAM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496	NDA	United Therapeutics Corporation	66302-300-01	100 TABLET, EXTENDED RELEASE in 1 BOTTLE (66302-300-01)	2013-12-20
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496	NDA	United Therapeutics Corporation	66302-300-02	1 BLISTER PACK in 1 CARTON (66302-300-02) / 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK	2013-12-20
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496	NDA	United Therapeutics Corporation	66302-302-01	100 TABLET, EXTENDED RELEASE in 1 BOTTLE (66302-302-01)	2013-12-20
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496	NDA	United Therapeutics Corporation	66302-302-02	1 BLISTER PACK in 1 CARTON (66302-302-02) / 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK	2013-12-20
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496	NDA	United Therapeutics Corporation	66302-310-01	100 TABLET, EXTENDED RELEASE in 1 BOTTLE (66302-310-01)	2013-12-20
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496	NDA	United Therapeutics Corporation	66302-310-02	1 BLISTER PACK in 1 CARTON (66302-310-02) / 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK	2013-12-20

Orenitram Supplier Landscape Analysis

Last updated: February 19, 2026

This report details the global supply chain for Orenitram (selexipag) and identifies key manufacturers and suppliers of the active pharmaceutical ingredient (API) and finished drug product. The analysis focuses on the current market, regulatory considerations, and potential supply risks.

What is Orenitram and its Market Position?

Orenitram is a prostacyclin receptor (IP receptor) agonist used for the treatment of pulmonary arterial hypertension (PAH). It is marketed by Actelion Pharmaceuticals, now a subsidiary of Johnson & Johnson. The drug's mechanism of action targets vasodilation and anti-proliferative effects in the pulmonary arteries.

Orenitram was approved by the U.S. Food and Drug Administration (FDA) in December 2013 and by the European Medicines Agency (EMA) in 2014. Its approval marked a significant advancement in PAH therapy, offering an orally administered option that improved exercise capacity and reduced the risk of clinical worsening in PAH patients.

The global PAH market is projected to grow, driven by increasing disease prevalence, improved diagnosis, and the development of novel therapies. Orenitram holds a notable share within this market, competing with other prostacyclin analogs and endothelin receptor antagonists.

Who are the Primary Manufacturers of Orenitram API?

The manufacturing of selexipag API is primarily handled by Actelion Pharmaceuticals, which maintains proprietary control over its production process. However, as with many pharmaceutical compounds, specialized contract development and manufacturing organizations (CDMOs) may be involved in specific stages of the API synthesis or production of key intermediates. These relationships are typically confidential and governed by strict quality agreements and intellectual property protection.

Based on publicly available information and general industry practices for complex small molecules like selexipag, potential CDMO involvement would likely focus on:

• Custom Synthesis of Intermediates: Producing specific chemical building blocks required for selexipag synthesis.
• Process Optimization and Scale-Up: Assisting in refining the manufacturing process for efficiency and cost-effectiveness at commercial scale.
• cGMP Manufacturing: Undertaking specific synthesis steps or full API production under Good Manufacturing Practices (GMP) for pharmaceutical use.

Identifying specific CDMOs for selexipag API without direct disclosure from Actelion/Johnson & Johnson is challenging. However, companies with demonstrated expertise in complex small molecule synthesis, chiral chemistry, and large-scale pharmaceutical API production are typically considered for such roles. Examples of globally recognized CDMOs that possess the capabilities for such work include:

• Lonza: A global leader in API manufacturing, offering comprehensive services from development to commercial scale.
• Catalent: Provides integrated services, including API development and manufacturing.
• Patheon (part of Thermo Fisher Scientific): A large CDMO with extensive experience in complex API synthesis.
• Samsung Biologics: While primarily known for biologics, they also have small molecule API capabilities.
• WuXi AppTec: A prominent China-based CDMO with a strong track record in API development and manufacturing.

These companies operate under strict regulatory oversight and have the infrastructure to meet the quality and compliance demands of pharmaceutical manufacturing.

What are the Key Suppliers for Orenitram Finished Drug Product?

The finished drug product, Orenitram tablets, is manufactured by Actelion Pharmaceuticals and Johnson & Johnson's pharmaceutical divisions. The formulation, tableting, and packaging are handled at their designated pharmaceutical manufacturing facilities. These facilities are subject to rigorous FDA, EMA, and other national regulatory body inspections to ensure compliance with cGMP standards.

The supply chain for the finished drug product involves:

• Primary Manufacturing Site(s): These are the core facilities responsible for the final drug product. Given Johnson & Johnson's global manufacturing network, these sites could be located in various regions, including the United States, Europe, or Asia. Specific locations are generally not disclosed for competitive and security reasons.
• Packaging and Labeling Sites: These sites may be co-located with primary manufacturing or operate as separate facilities. They are responsible for blister packaging, bottling, labeling, and preparing the product for distribution.
• Quality Control and Assurance Laboratories: Independent or integrated labs perform extensive testing to ensure the identity, purity, strength, and quality of the finished product.

Logistics and Distribution Networks:

Once manufactured, Orenitram is distributed through a complex global network involving:

• Wholesalers and Distributors: Companies like AmerisourceBergen, Cardinal Health, and McKesson in the U.S., or their international counterparts, play a crucial role in warehousing and distributing pharmaceutical products to pharmacies and healthcare providers.
• Specialty Pharmacies: For certain high-cost or complex therapies like PAH treatments, specialty pharmacies may be involved in dispensing directly to patients, offering additional patient support services.
• Third-Party Logistics (3PL) Providers: Actelion/J&J may utilize specialized 3PL companies for temperature-controlled storage and transportation of pharmaceuticals, ensuring product integrity throughout the supply chain.

The integrity of this supply chain is paramount, requiring robust cold chain management (if applicable, though Orenitram typically does not require strict cold chain) and adherence to track-and-trace regulations (e.g., the Drug Supply Chain Security Act in the U.S.) to prevent counterfeiting and ensure product authenticity.

What Regulatory Considerations Impact Orenitram Supply?

The supply of Orenitram is subject to stringent regulatory frameworks governing pharmaceutical manufacturing and distribution worldwide. Key considerations include:

• Good Manufacturing Practices (GMP): All manufacturing facilities involved in API synthesis and finished drug product production must comply with cGMP guidelines established by regulatory authorities such as the FDA (21 CFR Parts 210 & 211), EMA (EudraLex Volume 4), and others. This includes requirements for facility design, equipment validation, process control, personnel training, quality control, and documentation.
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers typically submit DMFs (in the U.S.) or ASMFs (in Europe) to regulatory agencies. These confidential documents contain detailed information about the API manufacturing process, controls, and specifications, which are reviewed by regulators as part of the drug product application. Actelion/J&J would reference these DMFs/ASMFs in their new drug applications (NDAs) or marketing authorization applications (MAAs).
• Site Inspections and Audits: Regulatory agencies conduct routine inspections of manufacturing facilities to verify ongoing compliance with GMP. Actelion/J&J also conducts its own audits of API suppliers and contract manufacturers to ensure quality standards are met.
• Impurity Profiling and Control: Strict limits are placed on impurities in both API and finished drug products. Manufacturers must demonstrate robust control over process-related impurities and degradation products. This includes identifying, quantifying, and qualifying any impurities above specified thresholds.
• Stability Testing: Manufacturers must conduct comprehensive stability studies to determine the shelf life of Orenitram under various storage conditions, ensuring the product remains safe and effective throughout its intended lifespan.
• Pharmacovigilance and Post-Market Surveillance: Post-approval, ongoing monitoring for adverse events and product quality issues is mandatory. Any significant supply chain disruptions or quality concerns can trigger regulatory investigations and actions.
• Supply Chain Security and Traceability: Regulations such as the U.S. Drug Supply Chain Security Act (DSCSA) mandate the serialization and tracking of prescription drugs to prevent counterfeit products from entering the supply chain. Similar regulations exist or are being implemented in other major markets.
• Import/Export Regulations: The international movement of APIs and finished pharmaceuticals is subject to customs regulations, import/export licenses, and specific documentation requirements in each country.

Any changes in the manufacturing process, suppliers, or specifications for Orenitram API or finished product require regulatory approval from agencies like the FDA and EMA, which can impact supply timelines and costs.

What are the Potential Risks and Challenges in the Orenitram Supply Chain?

The supply chain for Orenitram, like that of many complex pharmaceuticals, faces several potential risks and challenges:

• Single Sourcing or Limited Supplier Base: If Actelion/J&J relies on a very limited number of API manufacturers or intermediate suppliers, any disruption at these key sites can have a significant impact. This could be due to:
  • Quality Issues: A recall or shutdown resulting from GMP violations.
  • Capacity Constraints: Insufficient production capacity to meet global demand.
  • Geopolitical Instability: Disruptions in regions where suppliers are located.
  • Natural Disasters: Events impacting manufacturing infrastructure.
  • Company Solvency or Strategic Shifts: A supplier discontinuing production or being acquired.
• Intellectual Property (IP) Protection and Exclusivity: Orenitram is protected by patents. While patent expiry can lead to generic competition, the complexity of selexipag synthesis and the stringent regulatory requirements for generic approval may delay market entry by biosimil or generic manufacturers. This currently limits direct competition but also means the original innovator holds significant market power.
• Raw Material Sourcing and Volatility: The synthesis of selexipag involves multiple chemical steps, relying on a consistent supply of specific raw materials and intermediates. Fluctuations in the availability or cost of these upstream components, or disruptions in their own supply chains, can affect selexipag production.
• Regulatory Hurdles for New Suppliers: Introducing a new API supplier or CDMO into the approved supply chain for a drug like Orenitram is a lengthy and costly process. It requires extensive validation, comparability studies, and regulatory submissions and approvals. This inertia can make it difficult to quickly pivot to alternative suppliers in case of a disruption.
• Counterfeiting and Diversion: Despite track-and-trace measures, the high value of PAH medications makes them targets for counterfeiters and diversion schemes. Robust supply chain security is essential to mitigate these risks.
• Technical Complexity of Synthesis: Selexipag is a complex organic molecule with specific stereochemical requirements. Its synthesis demands specialized expertise and advanced manufacturing capabilities, which may not be widely available, further limiting the potential supplier pool.
• Geographic Concentration of Manufacturing: If a significant portion of the API or finished product manufacturing is concentrated in a single geographic region, that region becomes vulnerable to localized events (e.g., pandemics, trade disputes, environmental regulations).

Mitigating these risks typically involves strategies such as dual sourcing for critical intermediates, maintaining buffer stock, rigorous supplier qualification programs, and strong relationships with manufacturing partners.

Key Takeaways

• Orenitram (selexipag) API manufacturing is primarily controlled by Actelion Pharmaceuticals/Johnson & Johnson, with potential involvement of specialized CDMOs for intermediates or specific synthesis steps.
• Finished drug product manufacturing and distribution are managed through Johnson & Johnson's global pharmaceutical network and established distribution channels.
• The supply chain is subject to rigorous global regulatory oversight, including cGMP compliance, impurity control, and supply chain security mandates.
• Potential risks include reliance on a limited supplier base, complexity of synthesis, raw material volatility, and regulatory hurdles for supplier changes.

Frequently Asked Questions

1. Is selexipag API manufactured by multiple companies globally? Publicly available information does not confirm multiple primary manufacturers of selexipag API. Production is typically proprietary to Actelion Pharmaceuticals/Johnson & Johnson or their directly contracted CDMOs.

2. What are the primary geographic locations for Orenitram manufacturing facilities? Specific manufacturing site locations are not publicly disclosed by Actelion Pharmaceuticals/Johnson & Johnson for proprietary and security reasons.

3. Are there any generic versions of Orenitram currently available? As of the latest available information, there are no approved generic versions of Orenitram. Patent protection and the complexity of development and regulatory approval are contributing factors.

4. What is the typical lead time for qualifying a new API supplier for a drug like Orenitram? Qualifying a new API supplier for an established drug can take 18-36 months or longer, involving extensive process validation, analytical method transfer, cGMP compliance audits, and regulatory submissions and approvals.

5. Does the supply chain for Orenitram require specific cold chain storage? Orenitram does not typically require strict cold chain storage; it is usually stored at controlled room temperatures, but specific storage conditions are detailed on the product labeling.

Citations

[1] U.S. Food & Drug Administration. (2013, December 20). FDA approves Orenitram for pulmonary arterial hypertension. Retrieved from FDA Press Announcements

[2] European Medicines Agency. (n.d.). Orenitram. Retrieved from EMA website (specific document may vary based on current EMA database structure)

[3] Johnson & Johnson. (2017). Johnson & Johnson Completes Acquisition of Actelion. Retrieved from Johnson & Johnson Investor Relations

[4] U.S. Food & Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from FDA Regulations

[5] European Medicines Agency. (n.d.). EudraLex Volume 4 – GMP guidelines. Retrieved from EMA Guidance

[6] U.S. Food & Drug Administration. (n.d.). Drug Master Files. Retrieved from FDA Drug Master Files

[7] U.S. Food & Drug Administration. (n.d.). Drug Supply Chain Security Act (DSCSA). Retrieved from FDA DSCSA